Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

About this update from Prelude Therapeutics Incorporated

WILMINGTON, Del. , Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024 . On Monday, December 2 , at 11:30 a.m. ET , Kris Vaddi , Ph.D., Chief Executive Officer of Prelude, and Jane Huang , M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations . The recording will be archived and available on the Company’s website for 90 days. About Prelude Therapeutics Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com . Investor Contact: Robert Doody Senior Vice President, Investor Relations Prelude Therapeutics 484.639.7235 [email protected] Source: Prelude Therapeutics, Incorporated

View stock analysis, news, and events for Prelude Therapeutics Incorporated